Accès ouvert

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

Article scientifique 2016 Anglais

Résumé

The RAS/RAF/MEK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) pathway is one of the main signaling systems that manage proliferation, differentiation and cell survival, as well as cell cycle and apoptosis. 1 In this pathway, a cascade of phosphorylation events affects three key kinases: RAF, MEK (MAPK kinase) and ERK (MAP kinase). While MEK is not frequently mutated in human cancer, aberrant expression of MEK is observed in many different cancers. 1 , 2

Citer ce document

Puente, P., Muz, B., Jin, A., Azab, F., Luderer, M., Salama, N., Azab, A. (2016). MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. https://doi.org/10.1038/bcj.2016.7

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Pilar de la Puente Barbara Muz Abbey Jin Feda Azab Micah John Luderer Noha N. Salama Abdel Kareem Azab

Statistiques

Consultations : 2

Téléchargements : 0